Approval of pancreatic cancer trial with perioperative use of β-blocker and anti-inflammatory drug
Almost 1000 hours of cancer questions: PIT facts & figures
Omics-driven drug repurposing in rare cancers
Pantziarka, P. & Meheus, L. (2018). Omics-driven drug repurposing as a source of innovative therapies in rare cancers. Expert Opinion on Orphan Drugs, 6(9), 513-517. doi:10.1080/21678707.2018.1500690
Zoom in: ACF for patients
Zoom in: ACF for patients
Guy Buyens becomes new medical director of the Anticancer Fund
